127. Frontotemporal lobar degeneration Clinical trials / Disease details
Clinical trials : 89 / Drugs : 104 - (DrugBank : 33) / Drug target genes : 40 - Drug target pathways : 117
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04937452 (ClinicalTrials.gov) | June 3, 2021 | 16/6/2021 | Dopaminergic Therapy for Frontotemporal Dementia Patients | Dopaminergic Therapy for Frontotemporal Dementia Patients: an Interventional, Multi-site, Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of RTG Treatment in Patients With Behavioral FTD | Frontotemporal Dementia;Dementia;Aphasia, Primary Progressive;Pick Disease of the Brain;Brain Diseases;Central Nervous System Diseases;Nervous System Diseases;Neurocognitive Disorders;Mental Disorders;Neurodegenerative Diseases;Frontotemporal Lobar Degeneration;TDP-43 Proteinopathies;Proteostasis Deficiencies;Metabolic Disease;Aphasia;Speech Disorders;Language Disorders;Communication Disorders;Neurobehavioral Manifestations;Neurologic Manifestations | Drug: Rotigotine 4Mg/24Hrs Patch;Drug: Rotigotine 6Mg/24Hrs Patch;Drug: Placebo | I.R.C.C.S. Fondazione Santa Lucia | Alzheimer's Drug Discovery Foundation | Recruiting | 40 Years | 80 Years | All | 75 | Phase 2 | Italy |